This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neurogenetics  • Neurology, Other  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Timothy M. Miller, MD, PhD; Richard A. Smith, MD; Holly Kordasiewicz, PhD; Brian K. Kaspar, PhD

Arch Neurol. 2008;65(4):447-451. Published online February 11, 2008 (doi:10.1001/archneur.65.4.nnr70007).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

The identification of the genes and proteins involved in many neurodegenerative diseases¹ offers the exciting possibility of modifying those disease-linked proteins to develop novel, targeted therapies for diseases such as amyotrophic lateral sclerosis (ALS) or Huntington disease. In many of these diseases, the simplest modification—decreasing the amount of the offending protein—may represent a potent therapy. This realization, coupled with great strides in the techniques for decreasing specific proteins, has set the stage for moving these new therapies from animal models to clinical trials in the near future.

Multiple methods are currently being studied for their ability to decrease levels of unwanted proteins, including immunization strategies, small molecules, RNA interference (RNAi), and antisense oligonucleotides. Immunization strategies were an early favorite for clearing proteins from the central nervous system (CNS), with impressive results in Alzheimer disease . . . [Full Text of this Article]

MECHANISMS OF REPRESSION

EFFICACY IN ANIMAL MODELS

CONCERNS AND CONSIDERATIONS FOR USE IN HUMANS

AUTHOR INFORMATION

Author Affiliations: Neurosciences Department, University of California, San Diego, San Diego (Dr Miller); Ludwig Institute for Cancer Research, La Jolla, California (Drs Miller and Kordasiewicz); Center for Neurologic Study, La Jolla, California (Dr Smith); and Columbus Children's Research Institute and Ohio State University, Columbus (Dr Kaspar). Dr Miller is now with the Department of Neurology, Washington University School of Medicine, St Louis, Missouri.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gene Therapy and Informed Consent Decision Making: Nursing Research Directions
Kaspar et al.
Biol Res Nurs 2009;11:98-107.
ABSTRACT